Cenedella.de

Patient Advocate since 1977.


Leave a comment

German Medical Marijuana patients continued suffering despite the new law – from Hemp Magazine

After a small request from the federal government that the health insurance funds have to approve a therapy with medical cannabis before the statutory health insurance takes over the costs for the treatment, Frank Tempel, a sign of the drug policy of the left fraction, gives answers Questions that could be asked by those concerned. Meanwhile, the draft of a cannabis control law of the Green Bundestag fraction of March 2015 was rejected.
As beautiful as the new “Act on the Amendment to Narcotic Drugs and Other Provisions”, which came into effect on March 10, 2017, it raises a few dark shadows that could have a negative impact on the patient in the future. One of the central problems is the cost of a cannabis therapy by statutory health insurance. While pain patients receive the treatment in most cases, the world looks quite different in mental disorders, for example cases of ADHD or depression, Tempel reports on his website.
Requests for reimbursement would often be rejected in these patients. This also applies to patients who had already received a special permit from cannabis therapy from the “Federal Institute for Drugs and Medical Devices” prior to the entry into force of the Act. Because of this, it was already the first complaints of patients against the health insurance companies, it goes on. Temple also drew attention to the fact that there are some tips and hints to be able to claim the right to the costs.
The right to therapy with cannabis may be to patients if “a generally accepted medical standard” is either “not available” or “can not be used”, as well as “a not distant prospect perceptible positive effect on the course of the disease or on serious symptoms, “the Federal Government said in response to the small request from the left. According to the government, the treating physician must confirm these criteria and justify his decision against the health insurance company. But what helps if the cash registers?
Support the doctor
Tempel points out that it is easy for health insurance funds, especially through the second criterion, to refuse an application for the costs. This would be due to the lack of studies on the use of cannabis as a medicine, explains the deputy chairman of the Committee on Internal Medicine of the Bundestag. The 48-year-old, therefore, recommends “to refer to the introduction of a companion for which the patients have to participate if the costs of the therapy are to be reimbursed.”
In addition, he advises the physicians to assist in the completion of the application, since the health insurance companies would reject it at the smallest form defect. A sample application that could make life easier for the doctors offers the “Arbeitsgemeinschaft Cannabis as medicine” on their website http://www.cannabis-med.org . In order to take the perhaps still inexperienced doctor in this area further, the politician recommends in a discussion with the doctor also, professional-medically-based information to these to pass.
Where can I find a suitable doctor?
But already the search for a supervising doctor prepares the patient difficulties. The doctors would have little desire for more of the unpaid work and the effort they have to do, so temples. This is understandable. In addition to disputes with the health insurance companies, the treating physician must collect information about his patient and then pass it on to the “Federal Institute for Drugs and Medical Devices”. Temple once again refers to the “Cannabis as a medical community”, which can be asked for a doctor from the region who already has experience in prescribing medicinal hemp.
What to do if the cash office refuses?
If the applications, which are usually processed by the health insurance company within three weeks, but which can be withdrawn at the time the medical service is examined for examination of the application for five weeks, Tempel recommends that the supervisory authority, the relevant cash register. A protest may also be filed against the decision. A generator can also be found on the website of the “Arbeitsgemeinschaft Cannabis als Medizin”.
By a contradiction, the patient can also provide additional time, so that further advice can be brought into the boat, informs Tempel and writes to the following: “Do you have only courage to protest against the refusal of the health insurance company. There are cases in which the health insurance funds have approved it after the objection and a new application for reimbursement. “As a last option, the politician is considering taking legal action before the Social Court. The “Cannabis Consortium for Medicine” is even considering the support of the patient in court cases, provided that good prospects for success would exist, Tempel continues.
The Greens fail with a bill
Even though Germany has taken a clear step in the handling of marijuana through the “Act for the Amendment of Narcotic Drugs and Other Provisions” in the recent past, there are, of course, still sets-up parameters that can be worked on. The Greens tried their luck already two years ago in March 2015.
At that time, the Bundestag’s party draft a cannabis control law and presented it to the health committee of the Bundestag, which was voted on Wednesday. Although the Greens had the left fraction on their side, they failed with their draft, however, to the factions of the Union and the SPD, who opposed it.
The Greens drew attention to the fact that the cannabis control law had been an alternative to the prohibiting policy which had taken place here because it was “completely failed.” In the case of marijuana, which is the most widely used illegal drug in Germany, the criminal law provisions of the Narcotics Act should no longer apply , so the desire of the Greens. Instead, they pleaded in their template for a controlled, legal market with a regulated cannabis trading chain.
“The no from the Union and the SPD to our cannabis control law is a no to youth and consumer protection,” the “Ärtzeblatt” cites Greens Group spokeswoman Katja Dörner and the spokesman for drug and addiction policy, Harald Terpe. Cannabis is not harmless, the party made clear, precisely because of this, youth and consumer protection should not be left to the dealer.

Advertisements


Leave a comment

Kiffen on recipe? The cannabis doctor of Berlin

– by Thorsten Harmsen

Eva Milz (44) treats patients with medical cannabis. It means that the possibilities of the medium have not been fully developed.

Legal killing on prescription – critics see the meaning of the law, which the Bundestag decided in March. For the first time, doctors can prescribe cannabis. One of them is Eva Milz, psychiatrist with practice in Johannisthal.

The flowers of the hemp plant can relieve severe symptoms of the disease: – chronic pain, spastic paralysis, nausea, anxiety. But the plant can do more. This is my medical profession, who has dedicated himself to the development of the therapeutic potential of cannabis. There are only a few in Germany who believe that it is worth using cannabis as a therapy attempt .

Eva Milz knows about the restraint of many colleagues when dealing with the medicine. Because physicians are only allowed to prescribe medicinal cannabis if standard therapies do not help or have a “not very distant prospect of noticeable positive development on the course of the disease”. “Most doctors talk out and think you have to wear your head under your arm before you get cannabis,” says Eva Milz. But the fear of the means is unfounded.

Cannabis has already been used as a medicine in antiquity, including China and Egypt. This experience has been lost, says Eva Milz. For example, no medicine student learns that the body has many docking points for the substances from the hemp plant. These would be used to control messengers which ensure the functioning of nerve cells. “That’s part of every textbook,” says Eva Milz.

Nationwide it was about a thousand patients

She worked in many clinics, most recently as a psychiatrist at the Unfallkrankenhaus Berlin. She knows the spectrum of the means of modern medicine. It was addressed to cannabis as a therapy option for the first time in 2002. She then worked in patient advice for the medicine portal of a specialist publishing house. Multiple sclerosis patients, to whom she was talking, had discovered by accident – for example, when smoking a joint – that cannabis helps them as no other remedy.

Many asked if it was not legal. In working for the Federal Center for Health Education, Eva Milz again met people who were suffering from attention deficit hyperactivity disorder (ADHD) and reported that they were permanently in a state of decline after cannabis withdrawal.

When she founded her practice in 2015, she co-operated with the doctor, Franjo Grotenhermen, chairman of the Cannabis Consortium for Medicine (ACM). Eva Milz reviewed medical reports from patients from all over Germany and sent them to the Federal Institute for Drugs and Medical Devices. At the time, this granted exemptions for patients who were allowed to use cannabis.

Nationwide, it was about a thousand – 20 percent of ADHD patients. Those affected can not concentrate, neither learn nor work. They often find themselves in an offside position because they have an outcrop. But after the consumption of cannabis, they were able to concentrate, were able to learn and work. Many got their impulses under control.

Cannabis plant
The flowers of the hemp plant can alleviate serious symptoms.
Photo: Imago / CTK Photo
In ADHD, the THC appears to promote the concentration and focus of patients

According to Eva Milz, this is due to the variety of the ingredients of the hemp plant, especially the cannabinoids. “The main player that most know is the THC,” she says, expelled tetrahydrocannabinol. It has a harsh, psychoactive effect. “Cannabidiol, CBD, is quite unknown,” says Eva Milz. It acts like an opponent to the THC: anxiety and cramping, relaxing and anti-inflammatory. In addition, there are other cannabinoids, essential oils and aromas.

The components worked together. In ADHD, for example, the THC appears to be mainly focussing on the concentration and focus of the patient, says Eva Milz. The CBD probably solve the fear. Because impulsiveness and austerity have much to do with fear.

Perplexed, the psychiatrist read in the doctor’s letters that it was always the parents of young ADHD patients who asked if one could not legalize cannabis. Those who were closest to those affected had noticed that conventional drugs such as Ritalin slowed the sufferers, but also slowed creativity and liveliness. Cannabis had been an alternative.

In multiple-sclerosis patients, the agent for pain and muscle cramps is also effective, because both parts – THC and CBD – are also present, says Eva Milz. A list of 14 varieties of medicinal cannabis blossoms with different dosages shows how diverse the remedy is.

“I have been waiting for the critical questions of cannabis opponents for two years”

Many people think of cannabis first drug, possible addiction and its consequences. But even these are well controlled by an experienced doctor, says Eva Milz. It is reminiscent of conventional drugs that trigger the most severe dependencies. Cannabis with its comparatively mild withdrawal symptoms could possibly serve as a substitute.

One missing Eva Milz: “I have been waiting for the critical questions of cannabis opponents for two years, but I do not get them.” Instead, desperate patients came to her, who had been thrown out by other doctors – as supposedly addicts who were on detours Material wanted to come.

The doctor is inter alia with researchers at a university in conversation. Studies are being conducted on the use of cannabis flowers in Tourette’s syndrome, ADHD and other diseases where the drug is already being used. “I would like to have 30 to 50 preparations, which I can use as necessary,” she says. It is used for inflammatory diseases, anxiety, sleep disorders, neurodermatitis, migraine and other ailments.

One problem is the cost. The health insurance funds approve only about half of the applications. But a treatment can cost up to 3000 euros a month. For one gram of cannabis, the pharmacies demand 22 euros. Many could not afford it.

– Quelle: http://www.berliner-kurier.de/28240224 ©2017


Leave a comment

The chairman of the German Association for Cannabis as Medicine Dr. Franjo Grotenherman, has entered an “indefinite” hunger strike until Germany “decriminalize all citizens who need cannabis to treat their serious diseases.”

On August 17, 2017, I entered an indefinite hunger strike. The objective of refusing to accept any food is to decriminalize all citizens who need cannabis to treat their serious diseases.

On March 10, 2017, a much-debated law on cannabis as a medicine went into effect in Germany. It was the declared aim of the legislature to allow all patients who need a therapy with cannabis medicines to do so. The law, however, proves itself in practice as bureaucratic. Therefore, a treatment with cannabis and cannabinoids is unattractive for doctors who in principle support such therapy. Many patients do not find a doctor who allows them legal access to the needed treatment.

The legislator has taken a great step into the right direction. However, many patients are still dependent on a still as illegal regarded treatment. They face criminal sanctions. This is no longer acceptable. Therefore a basic clarification in the narcotics law must be established. The prosecution of patients to whom a doctor has certified the need for a therapy with cannabis must end.

Already today, the German Narcotics Law allows prosecutors to stop a criminal case in the case of a „minor debt“. This possibility is mainly applied in cases of possession of small amounts of cannabis. I urge that criminal proceedings should in principle also be stopped if accused citizens need cannabis for medical reasons. The need for a cannabis therapy should not be judged by the judiciary, a government agency or a health insurance company, but, as with other medical treatments, also by a doctor.

I also strongly support the uncomplicated access of patients to standardized preparations from the pharmacy. In this respect, it is necessary to improve the existing law. However, the prosecution of the remaining losers of the legal situation must also be ended. I am not aware of a convincing argument by which patients‘ prosecution can be maintained. A corresponding amendment to the Narcotics Act is, therefore, logical and unavoidable.

Franjo Grotenhermen, born in 1957, studied medicine in Cologne. Medical practice in Rüthen (NRW) with a focus on therapy with cannabis and cannabinoids. Grotenhermen is the chairman of the German Association for Cannabis as Medicine (ACM), Executive Director of the International Association for Cannabinoid Medicines (IACM) and Chairman of the Medical Cannabis Declaration (MCD), as well as author of the IACM-Bulletin, which is available in several languages ​​on the website of the IACM. Grotenhermen is an associate of the Cologne nova-Institut in the department of renewable resources and author of numerous articles and books on the therapeutic potential of cannabis and cannabinoids, their pharmaco logy and toxicology. Among others, since 2008 he has been an expert on debates in the Health Committee of the German Bundestag on the medical use of cannabis products, most recently in September 2016.

franjo


Leave a comment

The State of Cannabusiness in Germany

The State of Cannabusiness in Germany

As a cannabis business executive, you undoubtedly have been following some of the significant events happening in Europe and you have asked yourself: “How does this affect my plans?”

It may be the German government establishing a nationwide medical marijuana program, or news about the Canadian companies buying or merging with their European counterparts that has your attention. But you know the times are a changin’ and you might want to benefit from this historic moment in our Industry.

For those companies that already have a strategic international plan in place, the opportunities are boundless.  Germany, a nation with 2.5 times the population of California, is leading the way with the a national, Federal-government approved, medical marijuana law already in place, and numerous regional efforts to establish recreational use are getting off the ground as I write this column.

Having been an advocate in California during the medical marijuana legalization push of 1990s, and now living here in Germany as they build their own regulated marketplace, it has been fun to be involved. I’d now like to share some of the organizations that may be able to help you and your company, if Europe is indeed on your radar.

Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the German federal government’s  Institute for Drugs and Medical Devices and is lead by Professor Dr. Karl Broich. Their website is www.bfarm.de and they are basically the cannabis bureau of Germany, charged with implementing the medical marijuana law.  Interestingly, they will also be the sole purchaser of foreign-produced medical marijuana products, and then oversee the distribution exclusively though licensed pharmacies.

So Germans will be going to their local pharmacy to obtain their medicine, which officially should be paid by their insurance company.  Of course, the details are still being worked out, and I know of at least two lawsuits against insurance companies not paying for their clients medicine.

Last month, the BfArM put out a call for bids for the first ten authorized grow licenses in the history of Germany.  Negotiations are underway and the winning bidders should be announced shortly.  We will keep you updated on this, and all important details emanating from Europe, in future columns.

The Deutscher Hanfverband (DHV) is the German Hemp Association in Berlin and a fantastic resource and advocacy organization. They have been instrumental in getting the country to this point and their website is https://hanfverband.de I highly recommend signing up for their newsletter (which can easily be translated.)  Their next big event is the Hanf Parade in Berlin in August which will bring together over 10,000 advocates calling for open access.

For companies that want to get serious about being in Europe, the best organization I know of is the German Trade and Investment office located in Berlin which is part of the German Federal Ministry of Economic Affairs. Their website is www.gtai.de.

Their knowledge is vast, their connections incredible, and there is no charge for their services. They want to make it easy for international companies in our space to help Germany build their regulated marketplace. They provide advanced research, site-selection, tax information. And.. they are just an email or phone call away.

Of course, there are a total of 51 independent states that make up Europe and 28 of those make up the European Union.  To some degree all of these countries are changing the way they treat medical marijuana and CBD products.

If you are looking for some opportunities in this region, I would suggest looking not only at Germany, but also The Netherlands, Spain, United Kingdom, Switzerland, and the Czech Republic. Although Israel is not in the EU region, their expertise, leading edge research, products and capabilities are to be noted.

Before concluding, I need to give a shout out to Mr. Alex Rogers and his team at ICBC Berlin who put together one of the best industry events I have ever attended.  Back in April, in Berlin, almost 1000 attendees and exhibitors from throughout the world gathered to share information, make connections and close business deals.

Congressman Dana Rohrabacher, chairman of the Cannabis Caucus in the U.S. House of Representatives, was the keynote speaker and shared stories on his German ancestry, his first meeting with Ronald Reagan, and why legalizing our plant makes sense in so many ways.

Tommy Chong was also in attendance, was way coherent, and meeting him was definitely one of my personal highlights.  Yes, I admit it, I listened to his albums way back in 1971.

So I wish you a productive, successful and fun month ahead as we collectively take the next steps to “Make Cannabis Great Again” here in Europe, and wherever you are reading this in the world.

About The Author:


Leave a comment

Mary Jane Berlin 2017 From June 16 to 18 11:00 to 20:00 Funkhaus Berlin Nalepastr. 8th 12459 Berlin www.maryjane-berlin.de

Pack your bags and head off to Berlin

Last year, the first major hemp trade fair capital in the old post station took place, has been transformed into an idyllic place for the entire cannabis scene thanks to expert preparation. More than 100 international exhibitors, many snacks and very positive mood of pleasant reggae sound created beautiful atmosphere and let the many visitors closer to the marijuana issue, as it is common in everyday life. Since the enthusiasm also echoed many of those at home and do not want to stay away from the Berlin Hemp days on the Mary Jane Berlin in 2017, the special event expanded this year to almost double the size. The Mary Jane Berlin 2017 invites to convince even more people from the many useful properties of hemp Gewächses and bring connoisseurs of the topic of news as interesting facts about it.

For this reason, the team moved to Duc Anh Dang the consequences and saddles in 2017 in a larger area, which will provide enough space over 150 exhibitors. In the radio house Plänterwald are all well-known manufacturers of garden products, and cannabis products be represented at over 5000 m² of hall space and 2,000 m² outdoor area and present to interested visitors their latest achievements from 16 to 18 June. For a cheap day ticket of Mary Jane Berlin 2017 15 € – 30 € demanded euros for an even more favorable three-day ticket, which are wisely invested hemp friends. Rarely does one find the concentrated industry in one place concentrated even more rarely you meet the blended cream of the crop in the German capital.

Now since this country was cannabis as medicine finally accepted, is also to be expected with increased incidence of personalities from overseas. So 2017 offers the Mary Jane Berlin will naturally be a packed stage program in which more than twenty national and international specialists reveal their knowledge and are available for discussion groups available. A much larger hall is on the second held hemp trade fair for the dissemination of information to delegates whose discussions can therefore take place this year in an undisturbed setting. Among other Growing expert Mr. Jose will talk about cannabis cultivation in general, Rick Simpson strong case for a quick completion of Prohibition and Gerhard Seyfried reads from his book “Hemp in happiness.” Even the medical aspect is, of course, thoroughly lit and of course the driver’s license law is subject to a panel discussion.

Plenty of good reasons – to show the first warm rays of the Berlin city sun and to philosophize with many like-minded people about the changes in legislation, the benefits of Nutzgewächses and the failure of Prohibition – the Mary Jane Berlin 2017 therefore provides no doubt. Ways his favorite producers, editors of trade magazines, or even deserved praise speak out are on the June 16 to 18 in Berlin held hemp trade fair guarantees to satisfy given. Only the available repertoire of subjects for all undecided traders will slowly rar …

Let’s meet at:

Mary Jane Berlin 2017

From June 16 to 18

11:00 to 20:00

Funkhaus Berlin
Nalepastr. 8th
12459 Berlin

www.maryjane-berlin.de


2 Comments

Germany: Cultivation License, tender information

Germany-Bonn: medical equipment, pharmaceuticals and personal care products

http://ted.europa.eu/udl?uri=TED:NOTICE:131987-2017:TEXT:DE:HTML&src=0#id1042115-III.

2017 / S 070-131987

contract notice

Supplies

Directive 2014/24 / EU

Section I: Contracting authorities

I.1)Name and addresses

Federal Institute for Drugs and Medical Devices (BfArM)
Kurt-Georg-Kiesinger-Allee 3
Bonn
53175
Germany
Contact: Bundesinstitut für Arzneimittel und Medizinprodukte, Frau Stefanie Vogt
Phone: +49 228-2074124
E-Mail: Z122@bfarm.de
Fax : +49 228-2074352
NUTS Code: DEA22Internet address (es):Main address: http://www.bfarm.de

I.2)Common procurement strategy

I.3) Address from whichfurther information can be obtained:

The order documents are available free of charge for full and complete direct access at: https://www.evergabe-online.de/tenderdetails.html?id=156533
Further information can be obtained from the above-mentioned contact point (s)
Tenders or requests to participate must be submitted to the above mentioned contact point (s)

I.4)Type of the contracting authority

Ministry or other central or federal authority, including regional or local subdivisions

I.5)Main activity (s)

health

Section II: Subject

II.1)Scope of procurement

II.1.1) Titleattributed to the contract:

Cultivation, processing, storage, packaging and delivery of cannabis for medical purposes.

Reference number of the contract notice: 2281-1713

II.1.2) Mainterms of the sale or purchase:

33000000

II.1.3)Type of contract

Supplies

II.1.4)Short description:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

II.1.5)Estimated total value

II.1.6)Information about lots

Division of the contract into lots: yes
Offers are possible for all lots
Maximum number of lots to be awarded to a contracting authority: 7
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany

Lot No: 1

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 2

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference for the last three years (whether in the case of a single order or several contracts): the applicant receives 5 points per 50 kg delivery (A maximum of 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total quantity delivered in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 3

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference over the last three years (whether in the context of one or more contracts): The applicant shall be supplied per 50 kg of delivery 5 points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 4

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 5

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 6

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2021 to 2022, delivery quantity approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 7

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 2): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 8

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 2): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 9

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 3): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 10

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 3): delivery period 2021 to 2022, delivery quantity approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference over the last three years (whether in the context of one or more contracts): The applicant shall be supplied per 50 kg of delivery 5 points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation

III.1.1)Empowerment in professional or professional capacity, including requirements relating to the professional or trade registers

Listing and brief description of the conditions:

The tenderer’s declaration of entry in a professional or trade register or other proof of the professional qualification required in the State in which the applicant is established.

The client reserves the right to submit the following documents within the framework of the appraisal of the participation requests to a separate request:

– Local business register,

– a certificate from the competent social security authorities that social security contributions are paid in accordance with the regulations,

– the certificate of the competent professional association that the tenderer is a member there and who is contributing,

– Tax exemption certificate issued by the tax office,

– Declaration on the grounds of exclusion pursuant to §§ 123, 124 GWB.

III.1.2)Economic and financial capacity

List and brief description of the suitability criteria:

– the total turnover of the applicant in the last three financial years, if any.

– information on the applicant’s turnover in the area of ​​the cultivation, processing and delivery of cannabis for medical purposes, where available.

– an indication of the applicant’s turnover in the area of ​​the cultivation, processing and supply of medicinal plants during the last three financial years, where available.

– an indication of the existence of a professional or occupational liability insurance amounting to EUR 5 million (twice a year maximized) or the tenderer’s assurance to conclude such insurance in the case of the subdivision.

– submit the candidates’ annual accounts, if their publication is legally required by the applicant.

– indication that the financing of the contract is to be secured (financing by equity, shareholder loans, loans from a credit institution or similar), as well as the insurer’s insurance A corresponding commitment from the financing credit institution.

III.1.3)Technical capacity and professional capacity

List and brief description of the suitability criteria:

Information on the tenderer ‘s previous contracts for the cultivation, processing and delivery of medical cannabis in the last three years, if any (list showing the contract value, the delivery quantity, the delivery period and the recipient of the service and, where available, Country competent authority in accordance with Article 23 of the “Unity Convention 1961 on Narcotics” concluded in New York on 30 March 1961).

– information on the tenderer’s references to contracts for the cultivation, processing and delivery of medicinal plants carried out in the past three years, where available (list showing the contract value, the delivery volume, the delivery period and the beneficiary).

– indication of the technical personnel to be used by the tenderer in connection with the service.

– information on the equipment, equipment and technical equipment of the contractors to carry out the contract.

Minimum standards required:

At least one reference for the purpose of cultivation, processing and delivery of medicinal cannabis (minimum quantity of 50 kg) or a contract for the cultivation, processing and supply of medicinal plants (minimum 50 kg) for the last three years. A reference to a contract for the planting and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to a variety of different beneficiaries, in accordance with Article 23 of the “Unified Convention on Narcotic Drugs” And the total quantity delivered is at least 50 kg. As a reference about an order to cultivate,

III.1.5)Information about reserved contracts
III.2)Conditions relating to the contract

III.2.2)Conditions relating to the performance of the contract:

Permission according to § 3 Drugs Act.

Permission according to § 13 Arzneimittelgesetz.

III.2.3)Personnel responsible for execution of the contract

Obligation to indicate the names and professional qualifications of the persons responsible for the execution of the contract

Section IV: Procedure

IV.1)Description

IV.1.1) Type ofprocedure

negotiated procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system (DPS)

IV.1.4) Informationabout reduction of the number of operators or solutions to be taken during the negotiation or dialogue

The succession of the procedure in successive stages in order to gradually reduce the number of solutions to be discussed and / or the tenders to be negotiated
IV.1.5)Information about a negotiated procedure
IV.1.6)Information about electronic auction

IV.1.8) Informationabout the Procurement Agreement (GPA)

The contract is covered by the Procurement Agreement: no
IV.2)Administrative informationIV.3)
IV.2.1)Previous publication concerning this procedure

IV.2.2)Time-limit for receipt of tenders or requests to participate

Day: 05/06/2017
Local Time: 12:00

IV.2.3)Time-limit for receipt of tenders or requests to participate:

Day: 28/06/2017

IV.2.4)Language (s) in which tenders or requests to participate may be drawn up:

German

IV.2.6)Minimum time frame during which the tenderer must maintain the tender

Duration in months: 6 (from the date of receipt of tenders)
IV.2.7)Conditions for opening tenders

Section VI: Additional information

VI.1)Information about a return of the contract

This is a recurring job: yes
Estimated timing for further notices:

02/01/2021.

VI.2)Information about electronic work processes

No. VI.3)Additional information:

Details of the invitation to tender and of the documents to be submitted can be found in the tender form “Procurement procedure for the cultivation, processing, storage, packaging and delivery of cannabis for medical purposes, here: Invitation to submit applications for participation”, which forms part of the tender documents.

This procurement procedure will be carried out electronically on the website of the eVergabe platform ( www.evergabe-online.de ).

Please note that the free download of the tender documents is only for a first view. In order to participate in the tender, you must apply for participation. Only if you apply for the tender, you will be actively informed about any changes to the tender documents and will be able to ask questions about the tender or receive the answers.

Any legal or professional questions concerning the award procedure or the tender documents must be addressed to the eVergabe platform.

VI.4)Procedures for appeal / review

VI.4.1) Bodyresponsible for appeal procedures

Awarding Office of the
Confederation Villemombler Straße 76
Bonn
53123
Germany
VI.4.2)Body responsible for appeal procedures

VI.4.3)Lodging of appeals

Precise information on the time limits for lodging appeals:

Section 160 GWB

(1) The awarding authority shall initiate a review procedure only upon request.

2. Any undertaking which is interested in the public contract or the concession and who asserts an infringement in its rights pursuant to Article 97 (6) by not observing public procurement rules shall have the right to submit applications. It must be shown that the alleged infringement of the public procurement rules has caused or is likely to result in damage to the company.

(3) The application is inadmissible in so far as:

1. the applicant has recognized the alleged infringement of public procurement rules before submitting the request for review and has not complained to the contracting authority within a period of ten calendar days; The expiry of the time limit pursuant to Section 134 (2) shall remain unaffected,

2. Infringements of public procurement rules which are discernible on the basis of the notice shall not be complained to the contracting authority not later than the expiry of the period set out in the notice of invitation to tender,

3. Infringements of the public procurement rules, which are only recognizable in the tender documents, are not complained against the contracting authority at the latest until the expiry of the deadline for the application or tender,

4. have passed more than 15 calendar days after receipt of the notice of the contracting authority not to remedy a complaint.

VI.4.4)Service from which information about the lodging of appeals may be obtained

Awarding Office of the
Confederation Villemombler Straße 76
Bonn
53123
Germany

VI.5)Date of dispatch of this notice:

04/04/2017